302 related articles for article (PubMed ID: 17335293)
1. The role of induction therapy for resectable non-small cell lung cancer.
Stinchcombe TE; Socinski MA
Drugs; 2007; 67(3):321-32. PubMed ID: 17335293
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant therapy for resectable non-small cell lung cancer with mediastinal lymph node involvement.
Tieu BH; Sanborn RE; Thomas CR
Thorac Surg Clin; 2008 Nov; 18(4):403-15. PubMed ID: 19086609
[TBL] [Abstract][Full Text] [Related]
3. Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial).
Kocher F; Pircher A; Mohn-Staudner A; Romeder F; Duller W; Steinmaurer M; Eckmayr J; Schmid T; Hilbe W; Fiegl M; Greil R
Lung Cancer; 2014 Sep; 85(3):395-400. PubMed ID: 25043642
[TBL] [Abstract][Full Text] [Related]
4. [Multimodal treatment of non small cell lung cancer].
Stoelben E; Digel W; Henke M; Passlick B
Zentralbl Chir; 2006 Apr; 131(2):110-4. PubMed ID: 16612776
[TBL] [Abstract][Full Text] [Related]
5. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer.
van Meerbeeck JP; Kramer GW; Van Schil PE; Legrand C; Smit EF; Schramel F; Tjan-Heijnen VC; Biesma B; Debruyne C; van Zandwijk N; Splinter TA; Giaccone G;
J Natl Cancer Inst; 2007 Mar; 99(6):442-50. PubMed ID: 17374834
[TBL] [Abstract][Full Text] [Related]
6. Comparison of neoadjuvant cisplatin-based chemotherapy versus radiochemotherapy followed by resection for stage III (N2) NSCLC.
Pezzetta E; Stupp R; Zouhair A; Guillou L; Taffé P; von Briel C; Krueger T; Ris HB
Eur J Cardiothorac Surg; 2005 Jun; 27(6):1092-8. PubMed ID: 15896624
[TBL] [Abstract][Full Text] [Related]
7. Comparison of mediastinal lymph node status and relapse pattern in clinical stage IIIA non-small cell lung cancer patients treated with neoadjuvant chemotherapy versus upfront surgery: A single center experience.
Savic M; Kontic M; Ercegovac M; Stojsic J; Bascarevic S; Moskovljevic D; Kostic M; Vesovic R; Popevic S; Laban M; Markovic J; Jovanovic D
Thorac Cancer; 2017 Sep; 8(5):393-401. PubMed ID: 28671758
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a treatment strategy for optimising preoperative chemoradiotherapy in stage III non-small-cell lung cancer.
Phernambucq EC; Spoelstra FO; Paul MA; Senan S; Melissant CF; Postmus PE; Smit EF
Eur J Cardiothorac Surg; 2009 Dec; 36(6):1052-7. PubMed ID: 19616442
[TBL] [Abstract][Full Text] [Related]
9. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
[TBL] [Abstract][Full Text] [Related]
10. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.
Decaluwé H; De Leyn P; Vansteenkiste J; Dooms C; Van Raemdonck D; Nafteux P; Coosemans W; Lerut T
Eur J Cardiothorac Surg; 2009 Sep; 36(3):433-9. PubMed ID: 19502079
[TBL] [Abstract][Full Text] [Related]
11. Surgical resection of stage IIIA and stage IIIB non-small-cell lung cancer after concurrent induction chemoradiotherapy. A Southwest Oncology Group trial.
Rusch VW; Albain KS; Crowley JJ; Rice TW; Lonchyna V; McKenna R; Livingston RB; Griffin BR; Benfield JR
J Thorac Cardiovasc Surg; 1993 Jan; 105(1):97-104; discussion 104-6. PubMed ID: 8380477
[TBL] [Abstract][Full Text] [Related]
12. [Preoperative chemotherapy and chemoradiotherapy for non-small-cell bronchial cancers].
Milleron B; Mornex F; Martin E; Epaud C; Massiani MA
Cancer Radiother; 2002 Nov; 6 Suppl 1():105s-113s. PubMed ID: 12587388
[TBL] [Abstract][Full Text] [Related]
13. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805.
Albain KS; Rusch VW; Crowley JJ; Rice TW; Turrisi AT; Weick JK; Lonchyna VA; Presant CA; McKenna RJ; Gandara DR
J Clin Oncol; 1995 Aug; 13(8):1880-92. PubMed ID: 7636530
[TBL] [Abstract][Full Text] [Related]
14. Clinical issues in the management of non-small-cell lung cancer and the role of platinum-based therapy.
Socinski MA
Clin Lung Cancer; 2004 Mar; 5(5):274-89. PubMed ID: 15086966
[TBL] [Abstract][Full Text] [Related]
15. The role of surgery in N2 non-small cell lung cancer.
DeCamp MM; Ashiku S; Thurer R
Clin Cancer Res; 2005 Jul; 11(13 Pt 2):5033s-5037s. PubMed ID: 16000610
[TBL] [Abstract][Full Text] [Related]
16. The role of multimodality therapy in locoregional non-small cell lung cancer.
Martini N; Kris MG; Ginsberg RJ
Surg Oncol Clin N Am; 1997 Oct; 6(4):769-91. PubMed ID: 9309093
[TBL] [Abstract][Full Text] [Related]
17. The potential role of surgery after induction treatment.
Grunenwald DH; Albain KS
Semin Radiat Oncol; 2004 Oct; 14(4):335-9. PubMed ID: 15558509
[TBL] [Abstract][Full Text] [Related]
18. Multicenter phase II trial of accelerated cisplatin and high-dose epirubicin followed by surgery or radiotherapy in patients with stage IIIa non-small-cell lung cancer with mediastinal lymph node involvement (N2-disease).
Phernambucq EC; Biesma B; Smit EF; Paul MA; vd Tol A; Schramel FM; Bolhuis RJ; Postmus PE
Br J Cancer; 2006 Aug; 95(4):470-4. PubMed ID: 16909132
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant and adjuvant therapy for Stage III non-small cell lung cancer.
Watanabe SI; Nakagawa K; Suzuki K; Takamochi K; Ito H; Okami J; Aokage K; Saji H; Yoshioka H; Zenke Y; Aoki T; Tsutani Y; Okada M;
Jpn J Clin Oncol; 2017 Dec; 47(12):1112-1118. PubMed ID: 29136212
[TBL] [Abstract][Full Text] [Related]
20. Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response.
Pourel N; Santelmo N; Naafa N; Serre A; Hilgers W; Mineur L; Molinari N; Reboul F
Eur J Cardiothorac Surg; 2008 May; 33(5):829-36. PubMed ID: 18367406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
